Monoamine oxidase: Isoforms and inhibitors in Parkinson's disease and depressive illness

British Journal of Pharmacology

Volumn 147, Issue SUPPL. 1, 2006, Pages

  Youdim, Moussa B H ^a   Bakhle, Y S ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Alzheimer's disease; Antidepressants; Iron; Moclobemide; Monoamine oxidase A and B; Neuroprotection; Oxidative stress; Parkinson's disease; Rasagiline; Selegiline

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BEFLOXATONE; BENZYLAMINE; BROFAROMINE; CLORGYLINE; DOPAMINE; FLUOXETINE; IPRONIAZID; ISOCARBOXAZID; ISONIAZID; LAZABEMIDE; LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; N (2 PROPYNYL) 1 INDANAMINE; PHENELZINE; PHENETHYLAMINE; RASAGILINE; SELEGILINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ALZHEIMER DISEASE; BASAL GANGLION; CATALYSIS; CLINICAL TRIAL; COGNITION; DEAMINATION; DEPRESSION; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME METABOLISM; ENZYME SUBSTRATE; HUMAN; HYPERTENSION; LIVER TOXICITY; LOW DRUG DOSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATION KINETICS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS;

ANIMALS; CHOLINESTERASE INHIBITORS; DEMENTIA; DEPRESSIVE DISORDER; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INDANS; IRON; ISOENZYMES; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SELEGILINE;

EID: 30444437749     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706464     Document Type: Review

References (43)

1. BAKHLE, Y.S. (1990). Pharmacokinetic and metabolic properties of lung. Br. J. Anaesth., 65, 79-93.
2. BLANDINI, F. (2005). Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease? CNS. Drug. Rev., 11, 183-194.
3. BIRKMAYER, W., KNOLL, J., RIEDERER, P., YOUDIM, M.B., HARS, V. & MARTON, J. (1985). Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J. Neural. Transm., 64, 113-127.
4. BIRKMAYER, W., RIEDERER, P., YOUDIM, M.B.H. & LINAUER, W. (1975). The potentiation of the anti-akinetic effect after L-dopa treatment by an inhibitor of MAO-B, L-deprenyl. J. Neural. Transm., 36, 303-326.
5. BONNET, U. (2003). Moclobemide: therapeutic use and clinical studies. CNS. Drug. Rev., 9, 97-140.
6. BOTTLAENDER, M., DOLLE, F., GUENTHER, I., ROUMENOV, D., FUSEAU, C., BRAMOULLE, Y., CURET, O., JEGHAM, J., PINQUIER, J.L., GEORGE, P. & VALETTE, H. (2003). Mapping the cerebral monoamine oxidase type A: positron emission tomography characterization of the reversible selective inhibitor [11C]befloxatone. J. Pharmacol. Exp. Ther., 305, 467-473.
7. BOYER, E.W. & SHANNON, M. (2005). The serotonin syndrome. N. Engl. J. Med., 352, 1112-1120.
8. COLLINS, G.G.S., SANDLER, M., WILLIAMS, E.D. & YOUDIM, M.B.H. (1970). Multiple forms of human brain monoamine oxidase. Nature, 225, 817-820.
9. COLZI, A., D'AGOSTINI, F., CESURA, A.M., BORRONI, E. & DA PRADA, M. (1993). Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo. J. Pharmacol. Exp. Ther., 265, 103-111.
10. DAVIDSON, J.R. (2003). Pharmacotherapy of social phobia. Acta. Psychiatr. Scand., 417 (Suppl), 65-71.
11. FINBERG, J.P. & TENNE, M. (1982). Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br. J. Pharmacol., 77, 13-21.
12. FINBERG, J.P., TENNE, M. & YOUDIM, M.B. (1981). Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br. J. Pharmacol., 73, 65-74.
13. FINBERG, J.P., WANG, J., BANKIEWICZ, K., HARVEY-WHITE, J., KOPIN, I.J. & GOLDSTEIN, D.S. (1998). Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1- aminoindan (rasagiline) in the monkey. J. Neural. Transm. Suppl., 52, 279-285.
14. FINBERG, J.P. & YOUDIM, M.B. (1985). Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Br. J. Pharmacol., 85, 541-546.
15. GAL, S., ZHENG, H., FRIDKIN, M. & YOUDIM, M.B.H. (2005). Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. II; in vivo selective brain monoamine oxidase inhibition and prevention of MPTP induced striatal dopamine depletion. J. Neurochem., 95, 79-88.
16. GINGRICH, J.A. (2002). Mutational analysis of the serotonergic system: recent findings using knockout mice. Curr. Drug Targets CNS Neurol. Disord., 1, 449-465.
17. GREEN, A.R., MITCHELL, B.D., TORDOFF, A.F. & YOUDIM, M.B. (1977). Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol., 60, 343-349.
18. GREEN, A.R. & YOUDIM, M.B. (1975). Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br. J. Pharmacol., 55, 415-422.
19. GRUNBLATT, E., MANDEL, S., JACOB-HIRSCH, J., ZELIGSON, S., AMARIGLO, N., RECHAVI, G., LI, J., RAVID, R., ROGGENDORF, W., RIEDERER, P. & YOUDIM, M.B. (2004). Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural. Transm., 111, 1543-1573.
20. HAEFELY, W., BURKARD, W.P., CESURA, A.M., KETTLER, R., LOREZ, H.P., MARTIN, J.R., RICHARDS, J.G., SCHERSCHLICHT, R. & DA PRADA, M. (1992). Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology (Berlin)., 106 (Suppl), S6-S14.
21. HEIKKILA, R.E., MANZINO, L., CABBAT, F.S. & DUVOISIN, R.C. (1984). Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine by monoamine oxidase inhibitors. Nature, 311, 467-469.
22. JOHNSTON, P. (1968). Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol., 17, 1285-1297.
23. KNOLL, J. & MAGYAR, K. (1972). Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol., 5, 393-408.
24. MANDEL, S., WEINREB, O., AMIT, T. & YOUDIM, M.B. (2005). Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain. Res. Brain. Res. Rev., 48, 379-387.
25. MELAMED, E. & YOUDIM, M.B. (1985). Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase. Br. J. Pharmacol., 86, 529-531.
26. MENDLEWICZ, J. & YOUDIM, M.B.H. (1983). L-Deprenyl, a selective monoamine oxidase type B inhibitor in the treatment of depression; a double blind examination. Br. J. Psychiat., 142, 507-511.
27. RIEDERER, P., SOFIC, E., RAUSCH, W.D., SCHMIDT, B., REYNOLDS, G.P., JELLINGER, K. & YOUDIM, M.B. (1989). Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem., 52, 515-520.
28. RIEDERER, P. & YOUDIM, M.B. (1986). Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with 1-deprenyl. J. Neurochem., 46, 1359-1365.
29. ROGERS, J.T., RANDALL, J.D., CAHILL, C.M., EDER, P.S., HUANG, X., GUNSHIN, H., LEITER, L., MCPHEE, J., SARANG, S.S., UTSUKI, T., GREIG, N.H., LAHIRI, D.K., TANZI, R.E., BUSH, A.I., GIORDANO, T. & GULLANS, S.R. (2002). An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem., 277, 45518-45528.
30. SAGI, Y., DRIGUES, N. & YOUDIM, M.B.H. (2005). The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats. Br. J. Pharmacol., 146, 553-560.
31. SYMES, A.L., SOURKES, T.L., YOUDIM, M.B., GREGORIADIS, G. & BIRNBAUM, H. (1969). Decreased monoamine oxidase activity in liver of iron-deficient rats. Can. J. Biochem., 47, 999-1002.
32. YAMAMOTO, M. (2001). Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background. J. Neurol., 248 (Suppl 3:III), 5-11.
33. YOUDIM, M.B. & BUCCAFUSCO, J.J. (2005). Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci., 26, 27-35.
34. YOUDIM, M.B.H., COLLINS, G.G.S., SANDLER, M., BEVAN-JONES, A.B., PARE, C.M. & NICHOLSON, W.J. (1972). Human brain monoamine oxidase, multiple forms and selective inhibitors. Nature, 236, 225-228.
35. YOUDIM, M.B.H., EDMONDSON, D. & TIPTON, K.F. (2005). Monoamine oxidases and their inhibitors. Nat. Rev. Neurosci. (in press).
36. YOUDIM, M.B.H., FINBERG, J.P.M. & TIPTON, K.F. (1988). Monoamine oxidase. In: Advances in Experimental Pharmacology. Catecholamine. II. ed. Trendelenburg, U. & Weiner, U., pp. 119-192. Berlin: Springer-Verlag.
37. YOUDIM, M.B. & GREEN, A.R. (1975). Biogenic monoamine metabolism and functional activity in iron-deficient rats: behavioural correlates. Ciba. Found Symp., 51, 201-225.
38. YOUDIM, M.B., GROSS, A. & FINBERG, J.P. (2001). Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol., 132, 500-506.
39. YOUDIM, M.B. & WEINSTOCK, M. (2004). Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology, 25, 243-250.
40. YOUDIM, M.B., MARUYAMA, W. & NAOI, M. (2005). Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiParkinsonian drug, rasagiline. Drugs Today, 41, 369-391.
41. YOUDIM, M.B., WOODS, H.F., MITCHELL, B., GRAHAME-SMITH, D.G. & CALLENDER, S. (1975). Human platelet monoamine oxidase activity in iron-deficiency anaemia. Clin. Sci. Mol. Med., 48, 289-295.
42. ZECCA, L., YOUDIM, M.B., RIEDERER, P., CONNOR, J.R. & CRICHTON, R.R. (2004). Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci., 5, 863-873.
43. ZHENG, H., GAL, S., FRIDKIN, M., WEINER, R.L. & YOUDIM, M.B.H. (2005). Novel multifunctional neuroprotective iron chelator-monoamine oxidase drugs for neurodegenerative diseases: I. in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem., 95, 68-78.